about
Mechanisms of adaptation of the hepatic vasculature to the deteriorating conditions of blood circulation in liver cirrhosisPAI-1 4G-4G, MTHFR 677TT, V Leiden 506Q, and Prothrombin 20210A in Splanchnic Vein Thrombosis: Analysis of Individual Patient Data From Three Prospective Studies.Therapeutic effects and complications of simplified pericardial devascularization for patients with portal hypertension.N-acetylcysteine modulates angiogenesis and vasodilation in stomach such as DNA damage in blood of portal hypertensive ratsCelecoxib and octreotide synergistically ameliorate portal hypertension via inhibition of angiogenesis in cirrhotic rats.Systemic and Splanchnic Lipopolysaccharide and Endothelin-1 Plasma Levels in Liver Cirrhosis before and after Transjugular Intrahepatic Portosystemic ShuntEvolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments.Diagnostic efficacy of noninvasive liver fibrosis indexes in predicting portal hypertension in patients with cirrhosis.Dihydroartemisinin restricts hepatic stellate cell contraction via an FXR-S1PR2-dependent mechanism.Restructuring of the vascular bed in response to hemodynamic disturbances in portal hypertensionAngiogenesis and Fibrogenesis in Chronic Liver Diseases.Molecular Mechanisms Leading to Splanchnic Vasodilation in Liver Cirrhosis.PAI-1 4G-4G and MTHFR 677TT in non-hepatitis C virus/hepatitis B virus-related liver cirrhosis.Evaluation of splenic perfusion and spleen size using dynamic computed tomography: Usefulness in assessing degree of liver fibrosis.Non-invasive Diagnosis of Oesophageal Varices Using Systemic Haemodynamic Measurements by Finometry: Comparison with Other Non-invasive Predictive Scores.Therapeutic siRNA targeting endothelial KDR decreases portosystemic collateralization in portal hypertension.The impact of clinically significant portal hypertension on the prognosis of patients with hepatocellular carcinoma after radiofrequency ablation: a propensity score matching analysis.Endothelin receptor blockers reduce shunting and angiogenesis in cirrhotic rats.Portal hypertension is associated with poor outcome of transarterial chemoembolization in patients with hepatocellular carcinoma.The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis.Metformin attenuates motility, contraction, and fibrogenic response of hepatic stellate cells in vivo and in vitro by activating AMP-activated protein kinase.Metformin attenuates motility, contraction, and fibrogenic response of hepatic stellate cells in vivo and in vitro by activating AMP-activated protein kinase.Intrahepatic angiogenesis increases portal hypertension in hepatitis B patients with cirrhosis.The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats.Research progress on signaling pathways in cirrhotic portal hypertension
P2860
Q26744190-303E2122-2E5E-4ABB-8CA5-66B621F01A3FQ36021986-C21A64DD-4E47-401F-8A97-F2625FBD29A9Q36183434-26C941AB-589E-4F4A-B614-F98AFBD5D224Q36290381-3A8FEB00-701F-4E46-8E6D-2A88951CA980Q37262768-720B1173-E3C0-4059-B1D8-40DC0CF9CFC4Q38418029-94C4AE3B-17FA-4621-BB47-9869E92BA6C2Q38446357-F57F09F2-A6C8-4EFF-9160-98487FA75DBAQ38618343-04A159E5-4352-4C66-80AA-0B9104C346D3Q38782445-4FD16643-AAA9-402F-A0B6-A02A2D687854Q39084642-31329301-785E-4076-9159-9B42F386E9EBQ39140170-2F6C407C-58FB-49B3-B923-34AFCD6AD6D3Q39237821-715C64E5-F0C0-4B7C-B37A-D58FB1249436Q40186562-B86AC181-3B90-40ED-9F13-72F511CAAAC3Q40261026-5F30591D-E992-4F63-966C-26E8108923A1Q41342244-6F8E812E-3C7C-4F67-9540-2AE48A769764Q47111424-FB067720-C4C0-4E8D-8316-4A9C47FC310DQ48040300-99B97A95-01A3-4576-9617-51F9771950B8Q48057773-39300519-C437-4D7F-B09D-1FD28AB4B407Q48155342-FCA277D7-DB9A-4DEC-9CEB-36CABD20AC63Q48331734-0683AFD4-EA93-463A-B7A5-BC7591763400Q50146306-2FAAB1B7-6474-4FE0-85D6-13A34399F94DQ50199296-FF1099FC-3C18-4618-9CA8-E0C37CA3BE14Q50242973-5D760ED6-B83F-4416-8068-E161FBAE27CAQ55340936-7A254096-CA68-494B-A2AE-10F4FA8FF29BQ57069571-9C6E5BC9-8521-45B0-B39E-7ADF651C2B4E
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Molecular pathophysiology of portal hypertension.
@en
Molecular pathophysiology of portal hypertension.
@nl
type
label
Molecular pathophysiology of portal hypertension.
@en
Molecular pathophysiology of portal hypertension.
@nl
prefLabel
Molecular pathophysiology of portal hypertension.
@en
Molecular pathophysiology of portal hypertension.
@nl
P2860
P356
P1433
P1476
Molecular pathophysiology of portal hypertension
@en
P2093
Mercedes Fernandez
P2860
P304
P356
10.1002/HEP.27343
P407
P577
2015-03-09T00:00:00Z